Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "amgen rank"

The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energy, AbbVie and eBay
Nasdaq

The Zacks Analyst Blog Highlights: Amgen, Cisco, NextEra Energ...

For Immediate Release Chicago, IL November 21, 2016 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Yahoo! Finance, 1 week ago
[x]  

2 images for "amgen rank"

StatNews.com, 3 days ago
StatNews.com, 1 week ago
Zacks.com

Novartis/Amgen Migraine Drug Positive in Phase III Study

Novartis AG NVS and partner Amgen Inc. AMGN announced positive top-line data from the second pivotal phase III study (STRIVE) on their calcitonin gene-related peptide (CGRP) receptor, AMG 334 (erenumab), for the prevention of episodic migraine. The ...
 Yahoo! Finance2 weeks ago
[x]  

Amgen Presents Osteoporosis Data; Parsabiv Approved in EU

Amgen, Inc. AMGN and partner UCB S.A. UCBJF announced results from the pivotal phase III BRIDGE study which showed that its pipeline candidate, romosozumab, significantly increases bone mineral density in men with osteoporosis. Romosozumab is a ...
 Yahoo! Finance2 weeks ago
[x]  
Investor's Business Daily

Amgen, Gilead, Lilly Champ At AbbVie's Humira Sales

Eli Lilly ( LLY ), Pfizer ( PFE ) and Gilead Sciences ( GILD ) are chipping away at AbbVie 's ( ABBV ) Humira sales, Credit Suisse analyst Vamil Divan said Monday after AbbVie missed Q3 expectations Friday, primarily on declining Humira sales. ...
 Investor's Business Daily1 month ago Eli Lilly, AbbVie Top Big Pharma Rankings For 2017  Investor's Business Daily1 month ago
ACQ Magazine

ABR Of Amgen Inc. (NASDAQ:AMGN) At 2.41

Analysts of diverse research units have planned alternate terminology to give Buy/Sell calls. Stockholders not habituated to a certain research broker study mechanism or lingo can lead into rating misinterpretations. As a result, Zacks introduced ...
 Markets Daily3 days ago Why Amgen is the 'Top Dividend Stock of the Nasdaq 100' With 2.8% Yield (AMGN)  ACQ Magazine6 days ago Put Players Pile On as Valeant Pharmaceuticals Intl Inc (VRX) Stock Sinks  Schaeffers Research1 month ago Amgen, Inc. (AMGN) Rewards Option Bears Despite Earnings Beat  Schaeffers Research1 month ago
[x]  
Zacks.com

Here's Why Amgen (AMGN) Stock Slid Over 10% Today

On Friday, shares of therapeutics company Amgen Inc. AMGN are sliding, down over 10% in afternoon trading after the company reported its third quarter earnings results. Earnings per share came in at $3.02, beating the Zacks Consensus Estimate of ...
 Zacks.com1 month ago Amgen Raises 2016 Guidance - Quick Facts  RTTNews.com1 month ago
[x]  

Amgen Q3 16 Earnings Conference Call At 5:00 PM ET

Amgen Inc. (AMGN) will host a conference call at 5:00 PM ET on Oct. 27, 2016, to discuss Q3 16 earnings results. To access the live webcast log on to http://investors.amgen.com/phoenix.zhtml-c=61656&p=irol-IRHome by RTT Staff Writer For ...
 RTTNews.com1 month ago AbbVie's (ABBV) CEO Richard Gonzalez on Q3 2016 Results - Earnings Call Transcript  Seeking Alpha1 month ago
Pharmafile

Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study

THOUSAND OAKS, Calif., Nov. 16, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive top-line results for erenumab from a global Phase 3, randomized, double-blind, placebo-controlled ST udy to evaluate the efficacy and safety of ...
 Drugs.com1 week ago Amgen and Novartis AG Keep Lead in Migraine Drug Race on Positive Phase III Data  BioSpace2 weeks ago Amgen boosted in race to market for migraine drug  Pharmafile2 weeks ago Novel drug reduces monthly migraine days  Formulary Journal2 weeks ago
[x]  

Amgen's Xgeva matches zoledronic acid in late-stage study in multiple myeloma-related bone complications but falls short of showing superiority

Results from a Phase 3 clinical trial assessing Amgen's (NASDAQ: AMGN ) XGEVA (denosumab) compared to zoledronic acid (ZA) for the prevention of bone complications in newly diagnosed multiple myeloma (MM)patients achieved its primary endpoint. Full ...
 Seeking Alpha1 month ago

Amgen To Present At Citi Biotech R&D Conference; Webcast At 11:00 AM ET

Amgen Inc. (AMGN) will present at the Citi Biotech R&D Conference. The event is scheduled to begin at 11:00 AM ET on Oct. 7,2016. To access the live webcast, log on at www.amgen.com by RTT Staff Writer For comments and feedback: ...
 RTTNews.com1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less